Stearoyl-CoA desaturase-1: a potential therapeutic target for neurological disorders
Melanie Loix, Sam Vanherle, Marta Turri, Stephan Kemp, Karl J. L. Fernandes, Jerome J. A. Hendriks, Jeroen F. J. Bogie · 2024
Read Stearoyl-CoA desaturase-1: a potential therapeutic target for neurological disorders by Melanie Loix, Sam Vanherle, Marta Turri, Stephan Kemp, Karl J. L. Fernandes, Jerome J. A. Hendriks, Jeroen F. J. Bogie (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11575020.txt.
Description
Melanie Loix and co-authors review a fat-processing enzyme as a drug target for brain diseases in a 2024 paper. The enzyme, SCD1, converts saturated fats into the monounsaturated kind that cell membranes prefer. Blocking it calms brain inflammation and guards neurons in models of multiple sclerosis, Alzheimer's, and Parkinson's disease. Benefits run from regrown myelin sheaths to rescued memory and less toxic protein clumping.
One inherited disease, though, gets better when fat traffic through the enzyme rises, which warns against blanket blocking. The review maps the cell-level paths behind both the help and the harm. Context decides whether this enzyme is a target or a lifeline, and the authors chart that context disease by disease.
Catalog record
| CREATOR | Melanie Loix, Sam Vanherle, Marta Turri, Stephan Kemp, Karl J. L. Fernandes, Jerome J. A. Hendriks, Jeroen F. J. Bogie |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |